Athenex Pharmaceutical Division and SunGen Pharma Announce Terbutaline Sulfate Injection Product Launch
Athenex Pharmaceutical | August 31, 2017
Athenex, Inc. a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer, today announced the launch of Terbutaline Sulfate Injection, the first product launch by Athenex Pharmaceutical Division (APD) through their joint venture with SunGen Pharma LLC – Athenex Pharmaceuticals.